Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meiyu Fang

Showing results (51-60 of 72) with videos related to

Pageof 8
Sort By:
Journal for Immunotherapy of Cancer|October 4, 2024
Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trialBixia Tang, Yu Chen, Yu Jiang, et al.
European Journal of Cancer (Oxford, England : 1990)|March 13, 2024
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanomaXiaoting Wei, Zhengyun Zou, Weizhen Zhang, et al.
The Lancet. Microbe|December 4, 2023
Durability and cross-reactive immune memory to SARS-CoV-2 in individuals 2 years after recovery from COVID-19: a longitudinal cohort studyLi Guo, Qiao Zhang, Xiaoying Gu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2026
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 StudyLisa Licitra, Makoto Tahara, Kevin Harrington, et al.
Experimental Hematology & Oncology|June 26, 2026
Safety, efficacy, and pharmacokinetics of eratrectinib (VC004) in solid tumors with NTRK fusions: phase 1 results from a phase 1/2 studyShengyu Zhou, Changgong Zhang, Guowen Wang, et al.
Cancer Letters|February 1, 2025
Phase Ib study of SCT200 combined with paclitaxel or docetaxel in patients with recurrent or metastatic head and neck squamous cell carcinoma following platinum-based chemotherapy and PD-1 antibodyJinguan Lin, Song Qu, Kunyu Yang, et al.
Signal Transduction and Targeted Therapy|June 8, 2026
Efficacy and safety of toripalimab in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): a phase 1b/2 studyYe Guo, Zhendong Li, Liqiong Xue, et al.
Cancer Treatment Reviews|November 18, 2025
Expert consensus on the combination of Anti-EGFR monoclonal antibodies and immune checkpoint inhibitors in the treatment of head and neck squamous cell carcinomaLiqiong Xue, Tingting Xu, Guochun Cao, et al.
Nature Medicine|June 28, 2024
Finotonlimab with chemotherapy in recurrent or metastatic head and neck cancer: a randomized phase 3 trialYuankai Shi, Wei Guo, Wei Wang, et al.
Cancer|August 2, 2024
Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody-drug conjugates-induced interstitial lung disease/pneumonitis: An expert consensus in ChinaChunwei Xu, Zhanhong Chen, Yuanli Xia, et al.
Pageof 8

Showing results (51-60 of 72) with videos related to

Sort By:
Pageof 8
Journal for Immunotherapy of Cancer|October 4, 2024
Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trialBixia Tang, Yu Chen, Yu Jiang, et al.
European Journal of Cancer (Oxford, England : 1990)|March 13, 2024
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanomaXiaoting Wei, Zhengyun Zou, Weizhen Zhang, et al.
The Lancet. Microbe|December 4, 2023
Durability and cross-reactive immune memory to SARS-CoV-2 in individuals 2 years after recovery from COVID-19: a longitudinal cohort studyLi Guo, Qiao Zhang, Xiaoying Gu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2026
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 StudyLisa Licitra, Makoto Tahara, Kevin Harrington, et al.
Experimental Hematology & Oncology|June 26, 2026
Safety, efficacy, and pharmacokinetics of eratrectinib (VC004) in solid tumors with NTRK fusions: phase 1 results from a phase 1/2 studyShengyu Zhou, Changgong Zhang, Guowen Wang, et al.
Cancer Letters|February 1, 2025
Phase Ib study of SCT200 combined with paclitaxel or docetaxel in patients with recurrent or metastatic head and neck squamous cell carcinoma following platinum-based chemotherapy and PD-1 antibodyJinguan Lin, Song Qu, Kunyu Yang, et al.
Signal Transduction and Targeted Therapy|June 8, 2026
Efficacy and safety of toripalimab in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): a phase 1b/2 studyYe Guo, Zhendong Li, Liqiong Xue, et al.
Cancer Treatment Reviews|November 18, 2025
Expert consensus on the combination of Anti-EGFR monoclonal antibodies and immune checkpoint inhibitors in the treatment of head and neck squamous cell carcinomaLiqiong Xue, Tingting Xu, Guochun Cao, et al.
Nature Medicine|June 28, 2024
Finotonlimab with chemotherapy in recurrent or metastatic head and neck cancer: a randomized phase 3 trialYuankai Shi, Wei Guo, Wei Wang, et al.
Cancer|August 2, 2024
Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody-drug conjugates-induced interstitial lung disease/pneumonitis: An expert consensus in ChinaChunwei Xu, Zhanhong Chen, Yuanli Xia, et al.
Pageof 8